SECONDARY MALIGNANCIES AFTER FCR AND FC TREATMENT IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA. ? SINGLE CENTER STUDY.
(Abstract release date: 05/21/15)
EHA Library. Byalik T. 06/12/15; 103029; PB1726
Disclosure(s): N.N. Blokhin Russian Cancer Research CenterOncohematology
Tatyana Byalik
Contributions
Contributions
Abstract
Abstract: PB1726
Type: Publication Only
Background
The combination of fludarabine, cyclophosphamide and rituximab (FCR) improved response rates and prolonged both overall survival (OS) and progression-free survival (PFS). On the basis of CLL8 trial FCR has become the standard treatment for fit patients with CLL.
Aims
In this report we presents of follow up results of FCR and FC therapy and adverse events as secondary malignancies.
Methods
117 patients (50 previously untreated and 67 with relapsed and refractory) received six courses of FCR or FC. Median age was 56,5 (range 28-73) for FCR group and 57 (range 38-76) for FC group. 52 patients were in Binet stage B and 15 in stage C for FCR group, 38 patients were in Binet stage B and 12 in stage C for FC group. OR was 91% with CR rate 57% for FCR group, 86% and 50% for FC group.
Results
At follow up period 120 months median overall survival in FCR group was 61,3 month, in FC group – 44,6 months, in previously untreated FCR group median OS was 89 months and OS was not reached for previously untreated FC group, progression-free survival were 42,4 months for previously untreated FCR group and 24,4 month for previously untreated FC group (p=0,01). Infection complications III-IV grade were appeared in 15 patients: 4 (6%) for FCR group and 11 (22%) for FC group. 5 patients died due to infection: 2 patients in FCR group (2,9%) and 3 patients in FC group (6%). Secondary malignancies were occurred at 10 patients (8,5%): 6 patients in FCR group (8,9%) and 4 – in FC group (8%). Of these 10 patients, 5 patients (4,2%) had a solid tumor (lung, bladder, colon), 1patient (0,8%) had a melanoma, 4 patients (3,4%) had a Richter transformation.
Summary
FCR chemoimmunotherapy is highly effective in patients with CLL. The frequency of secondary malignancies was 8,5%.
Keyword(s): B-CLL
Session topic: Publication Only
Type: Publication Only
Background
The combination of fludarabine, cyclophosphamide and rituximab (FCR) improved response rates and prolonged both overall survival (OS) and progression-free survival (PFS). On the basis of CLL8 trial FCR has become the standard treatment for fit patients with CLL.
Aims
In this report we presents of follow up results of FCR and FC therapy and adverse events as secondary malignancies.
Methods
117 patients (50 previously untreated and 67 with relapsed and refractory) received six courses of FCR or FC. Median age was 56,5 (range 28-73) for FCR group and 57 (range 38-76) for FC group. 52 patients were in Binet stage B and 15 in stage C for FCR group, 38 patients were in Binet stage B and 12 in stage C for FC group. OR was 91% with CR rate 57% for FCR group, 86% and 50% for FC group.
Results
At follow up period 120 months median overall survival in FCR group was 61,3 month, in FC group – 44,6 months, in previously untreated FCR group median OS was 89 months and OS was not reached for previously untreated FC group, progression-free survival were 42,4 months for previously untreated FCR group and 24,4 month for previously untreated FC group (p=0,01). Infection complications III-IV grade were appeared in 15 patients: 4 (6%) for FCR group and 11 (22%) for FC group. 5 patients died due to infection: 2 patients in FCR group (2,9%) and 3 patients in FC group (6%). Secondary malignancies were occurred at 10 patients (8,5%): 6 patients in FCR group (8,9%) and 4 – in FC group (8%). Of these 10 patients, 5 patients (4,2%) had a solid tumor (lung, bladder, colon), 1patient (0,8%) had a melanoma, 4 patients (3,4%) had a Richter transformation.
Summary
FCR chemoimmunotherapy is highly effective in patients with CLL. The frequency of secondary malignancies was 8,5%.
Keyword(s): B-CLL
Session topic: Publication Only
Abstract: PB1726
Type: Publication Only
Background
The combination of fludarabine, cyclophosphamide and rituximab (FCR) improved response rates and prolonged both overall survival (OS) and progression-free survival (PFS). On the basis of CLL8 trial FCR has become the standard treatment for fit patients with CLL.
Aims
In this report we presents of follow up results of FCR and FC therapy and adverse events as secondary malignancies.
Methods
117 patients (50 previously untreated and 67 with relapsed and refractory) received six courses of FCR or FC. Median age was 56,5 (range 28-73) for FCR group and 57 (range 38-76) for FC group. 52 patients were in Binet stage B and 15 in stage C for FCR group, 38 patients were in Binet stage B and 12 in stage C for FC group. OR was 91% with CR rate 57% for FCR group, 86% and 50% for FC group.
Results
At follow up period 120 months median overall survival in FCR group was 61,3 month, in FC group – 44,6 months, in previously untreated FCR group median OS was 89 months and OS was not reached for previously untreated FC group, progression-free survival were 42,4 months for previously untreated FCR group and 24,4 month for previously untreated FC group (p=0,01). Infection complications III-IV grade were appeared in 15 patients: 4 (6%) for FCR group and 11 (22%) for FC group. 5 patients died due to infection: 2 patients in FCR group (2,9%) and 3 patients in FC group (6%). Secondary malignancies were occurred at 10 patients (8,5%): 6 patients in FCR group (8,9%) and 4 – in FC group (8%). Of these 10 patients, 5 patients (4,2%) had a solid tumor (lung, bladder, colon), 1patient (0,8%) had a melanoma, 4 patients (3,4%) had a Richter transformation.
Summary
FCR chemoimmunotherapy is highly effective in patients with CLL. The frequency of secondary malignancies was 8,5%.
Keyword(s): B-CLL
Session topic: Publication Only
Type: Publication Only
Background
The combination of fludarabine, cyclophosphamide and rituximab (FCR) improved response rates and prolonged both overall survival (OS) and progression-free survival (PFS). On the basis of CLL8 trial FCR has become the standard treatment for fit patients with CLL.
Aims
In this report we presents of follow up results of FCR and FC therapy and adverse events as secondary malignancies.
Methods
117 patients (50 previously untreated and 67 with relapsed and refractory) received six courses of FCR or FC. Median age was 56,5 (range 28-73) for FCR group and 57 (range 38-76) for FC group. 52 patients were in Binet stage B and 15 in stage C for FCR group, 38 patients were in Binet stage B and 12 in stage C for FC group. OR was 91% with CR rate 57% for FCR group, 86% and 50% for FC group.
Results
At follow up period 120 months median overall survival in FCR group was 61,3 month, in FC group – 44,6 months, in previously untreated FCR group median OS was 89 months and OS was not reached for previously untreated FC group, progression-free survival were 42,4 months for previously untreated FCR group and 24,4 month for previously untreated FC group (p=0,01). Infection complications III-IV grade were appeared in 15 patients: 4 (6%) for FCR group and 11 (22%) for FC group. 5 patients died due to infection: 2 patients in FCR group (2,9%) and 3 patients in FC group (6%). Secondary malignancies were occurred at 10 patients (8,5%): 6 patients in FCR group (8,9%) and 4 – in FC group (8%). Of these 10 patients, 5 patients (4,2%) had a solid tumor (lung, bladder, colon), 1patient (0,8%) had a melanoma, 4 patients (3,4%) had a Richter transformation.
Summary
FCR chemoimmunotherapy is highly effective in patients with CLL. The frequency of secondary malignancies was 8,5%.
Keyword(s): B-CLL
Session topic: Publication Only
{{ help_message }}
{{filter}}